The C-allele of tissue inhibitor of metalloproteinases 2 is associated with increased magnitude of QT dispersion prolongation in elderly Chinese - 4-year follow-up study

Clinica Chimica Acta

Volumn 386, Issue 1-2, 2007, Pages 87-93

  Lin, Tsung Hsien ^a,b   Chiu, Herng Chia ^c   Lee, Ya Ting ^a   Su, Ho Ming ^a   Juo, Suh Hang Hank ^c   Voon, Wen Chol ^a,b   Lai, Wen Ter ^a,b   Sheu, Sheng Hsiung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Ageing; Chinese; Polymorphism; QT dispersion; Repolarization; Tissue inhibitor of metalloproteinases

Indexed keywords

GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ALLELE; ARTICLE; CALCULATION; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; QT DISPERSION; QT PROLONGATION; REPOLARIZATION; SCREENING; T WAVE;

AGED; AGED, 80 AND OVER; AGING; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FOLLOW-UP STUDIES; HUMANS; LONG QT SYNDROME; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 34548701595     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.08.004     Document Type: Article

References (35)

1. Fleg J.L., and Kennedy H.L. Cardiac arrhythmias in a healthy elderly population: detection by 24-hour ambulatory electrocardiography. Chest 81 (1982) 302-307
2. Reardon M., and Malik M. QT interval change with age in an overtly healthy older population. Clin Cardiol 19 (1996) 949-952
3. de Bruyne M.C., Hoes A.W., Kors J.A., Hofman A., van Bemmel J.H., and Grobbee D.E. QTc dispersion predicts cardiac mortality in the elderly. The Rotterdam study. Circulation 97 (1998) 467-472
4. Okin P.M., Devereux R.B., Howard B.V., Fabsitz R.R., Lee E.T., and Welty T.K. Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians. The Strong Heart Study. Circulation 101 (2000) 61-66
5. Aiba T., Shimizu W., Inagaki M., Hidaka I., Tatewaki T., and Sunagawa K. Transmural heterogeneity of the action potential configuration in the feline left ventricle. Circ J 67 (2003) 449-454
6. Shimizu W., and Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 98 (1998) 2314-2322
7. Ozawa T., Ito M., Tamaki S., et al. Gender and age effects on ventricular repolarization abnormality in Japanese general carriers of a G643S common single nucleotide polymorphism for the KCNQ1 gene. Circ J 70 (2006) 645-650
8. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 69 (2006) 636-645
9. Yasmin, McEniery C.M., O'Shaughnessy K.M., et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 26 (2006) 1799-1805
10. Ogata T., Shibamura H., Tromp G., et al. Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg 41 (2005) 1036-1042
11. Zhang B., Ye S., Herrmann S.M., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99 (1999) 1788-1794
12. Medley T.L., Cole T.J., Dart A.M., Gatzka C.D., and Kingwell B.A. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 24 (2004) 1479-1484
13. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
14. Hirano K., Sakamoto T., Uchida Y., et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 18 (2001) 748-752
15. Moshal K.S., Tyagi N., Moss V., et al. Early induction of matrix metalloproteinase-9 transduces signaling in human heart end stage failure. J Cell Mol Med 9 (2005) 704-713
16. Heymans S., Schroen B., Vermeersch P., et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112 (2005) 1136-1144
17. Lin T.H., Chiu H.C., Su H.M., et al. The D-allele of ACE polymorphism is associated with increased magnitude of QT dispersion prolongation in elderly Chinese - 4 years follow-up study. Circ J 71 (2007) 39-45
18. Lin T.H., Chiu H.C., Su H.M., et al. Association between fasting plasma glucose and left ventricular mass/hypertrophy over 4 years in a healthy population aged 60 and older. J Am Geriatr Soc 55 (2007) 717-724
19. Malik M., and Batchvarov V.N. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 36 (2000) 1749-1766
20. Haraguchi Y., Yoshinaga M., Sarantuya J., et al. Interval representative of transmural dispersion of repolarization in children and young adolescents with congenital long QT syndrome. Circ J 69 (2005) 78-82
21. Devereux R.B., and Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55 (1977) 613-618
22. Zhou Y., Yu C., Miao X., et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis 25 (2004) 399-404
23. Higham P.D., Furniss S.S., and Campbell R.W.F. QT dispersion and components of the QT interval in ischemia and infarction. Br Heart J 73 (1995) 32-36
24. Oikarinen L., Nieminen M.S., Viitasalo M., et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint reduction. J Hypertens 19 (2001) 1883-1891
25. Burlew B.S. Diastolic dysfunction in the elderly-the interstitial issue. Am J Geriatr Cardiol 13 (2004) 29-38
26. Guo C., and Piacentini L. Type I collagen-induced MMP-2 activation coincides with up-regulation of membrane type 1-matrix metalloproteinase and TIMP-2 in cardiac fibroblasts. J Biol Chem 278 (2003) 46699-46708
27. Herpel E., Pritsch M., Koch A., Dengler T.J., Schirmacher P., and Schnabel P.A. Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy. Histopathology 48 (2006) 736-747
28. Capasso J.M., Malhotra A., Remily R.M., Scheuer J., and Sonnenblick E.H. Effects of age on mechanical and electrical performance of rat myocardium. Am J Physiol 245 (1983) H72-H81
29. Robert V., Besse S., Sabri A., et al. Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest 76 (1997) 729-738
30. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
31. Li Y.Y., McTiernan C.F., and Feldman A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46 (2000) 214-224
32. Lovelock J.D., Baker A.H., Gao F., et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 288 2 (Feb 2005) H461-H468
33. Mukherjee R., Herron A.R., Lowry A.S., et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 97 (2006) 532-537
34. Sundstrom J., Evans J.C., Benjamin E.J., et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109 (2004) 2850-2856
35. Demacq C., de Souza A.P., Machado A.A., Gerlach R.F., and Tanus-Santos J.E. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta 365 (2006) 183-187